Free tool
FAERS Monitor: Sivextro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205436 or its brand name (Sivextro, Tedizolid Phosphate). Reports on generic versions are filed under their own applications.
Reports
803
Serious
528
66% of reports
Hospitalization
254
Death reported
51
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use110
- product use in unapproved indication88
- thrombocytopenia62
- anaemia51
- nausea45
- no adverse event43
- drug ineffective36
- pancytopenia34
- product availability issue33
- product dose omission issue32
- diarrhoea27
- rash25
- serotonin syndrome21
- vomiting21
- death19
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 10 |
| 2015 | 39 |
| 2016 | 34 |
| 2017 | 41 |
| 2018 | 55 |
| 2019 | 108 |
| 2020 | 83 |
| 2021 | 73 |
| 2022 | 62 |
| 2023 | 109 |
| 2024 | 69 |
| 2025 | 72 |
| 2026 | 48 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,356 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product availability issueSignal | 33 | 38.0 | 27.2 | 1,152 |
| serotonin syndromeSignal | 21 | 28.7 | 18.8 | 533 |
| pancytopeniaSignal | 34 | 15.9 | 11.5 | 462 |
| thrombocytopeniaSignal | 62 | 14.5 | 11.4 | 771 |
| product use in unapproved indicationSignal | 88 | 9.3 | 7.6 | 651 |
| anaemiaSignal | 51 | 7.0 | 5.4 | 259 |
| no adverse eventSignal | 43 | 6.2 | 4.6 | 185 |
| off label useSignal | 110 | 3.3 | 2.8 | 181 |
| product dose omission issueSignal | 32 | 2.9 | 2.0 | 37 |
| rash | 25 | 1.5 | 1.0 | 4 |
| nausea | 45 | 1.5 | 1.1 | 7 |
| vomiting | 21 | 1.2 | 0.8 | 0 |
| diarrhoea | 27 | 1.1 | 0.8 | 0 |
| drug ineffective | 36 | 0.7 | 0.5 | 4 |
| death | 19 | 0.6 | 0.4 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.